* Dynavax Technologies Corp DVAX.OQ DVAX.O is expected
to show
a rise in quarterly revenue when it reports results on May 8
for the period ending March 31 2024
* The Emeryville California-based company is expected to
report a
17.2% increase in revenue to $54.976 million from $46.93 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Dynavax Technologies
Corp is
for a loss of 2 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Dynavax
Technologies Corp is $27.00, above its last closing price
of $11.64.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.01 -0.01 0.00 Beat 100
Sep. 30 2023 -0.01 -0.01 0.10 Beat 766.7
Jun. 30 2023 -0.09 -0.09 0.03 Beat 132.7
Jan. 1 0001 -0.13 -0.13 -0.19 Missed -43.4
Dec. 0.43 0.43 0.45 Beat 5.3
31 2022
Jan. 1 0001 0.34 0.33 0.43 Beat 31.3
Jun. 30 2022 0.22 0.22 0.87 Beat 295.5
Mar. 31 2022 0.24 0.24 0.22 Missed -8.3
This summary was machine generated May 7 at 02:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)